{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:53:23Z","timestamp":1784854403399,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1994,11,1]],"date-time":"1994-11-01T00:00:00Z","timestamp":783648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[1994,11]]},"DOI":"10.1007\/bf01534430","type":"journal-article","created":{"date-parts":[[2005,4,19]],"date-time":"2005-04-19T11:51:50Z","timestamp":1113911510000},"page":"416-419","source":"Crossref","is-referenced-by-count":44,"title":["Histamine in immunotherapy of advanced melanoma: a pilot study"],"prefix":"10.1007","volume":"39","author":[{"given":"Kristoffer","family":"Hellstrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Naredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Lundholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Magnus","family":"Rudenstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svante","family":"Hermodsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Aszt\ufffdly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larsolof","family":"Hafstr\ufffdm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1990.8.7.1138","volume":"8","author":"MH Bar","year":"1990","unstructured":"Bar, MH, Sznol M, Atkins MB, et al (1990) Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 8: 1138?1147","journal-title":"J Clin Oncol"},{"key":"CR2","first-page":"137","volume":"13","author":"L Bergmann","year":"1990","unstructured":"Bergmann L, Weidmann E, Mitrou PS, et al (1990) Interleukin-2 in combination with interferon-? in disseminated malignant melanoma and advanced renal cell carcinoma. Onkologie 13: 137?140","journal-title":"Onkologie"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ijc.2910400314","volume":"40","author":"MJ Brunda","year":"1987","unstructured":"Brunda MJ, Belantoni D, Sulich V (1987) In vivo antitumour activity of combinations of interferon-? and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic function resembling natural killer cells. Int J Cancer 40: 365?371","journal-title":"Int J Cancer"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4049\/jimmunol.137.2.656","volume":"137","author":"K Hellstrand","year":"1986","unstructured":"Hellstrand K, Hermodsson S (1986) Histamine H2-receptor mediated regulation of human natural killer cell cytotoxicity. J Immunol 137: 656?660","journal-title":"J Immunol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-3083.1990.tb02814.x","volume":"31","author":"K Hellstrand","year":"1990","unstructured":"Hellstrand K, Hermodsson S (1990) A cell-to-cell interaction involving monocytes and non-T\/CD16+ natural killer (NK) cells is required for histamine H2-receptor mediated NK cell activation. Scand J Immunol 31: 631?645","journal-title":"Scand J Immunol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000235169","volume":"92","author":"K Hellstrand","year":"1990","unstructured":"Hellstrand K, Hermodsson S (1990) Synergistic NK cell activation by histamine and interleukin-2. Int Arch Allergy Appl Immunol 92: 379?389","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-3083.1991.tb01599.x","volume":"34","author":"K Hellstrand","year":"1991","unstructured":"Hellstrand K, Hermodsson S (1991) Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand J Immunol 34: 741?752","journal-title":"Scand J Immunol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.4049\/jimmunol.145.12.4365","volume":"145","author":"K Hellstrand","year":"1990","unstructured":"Hellstrand K, Asea A, Hermodsson S (1990) Role of histamine in natural killer cell mediated resistance against tumor cells. J Immunol 145: 4365?4370","journal-title":"J Immunol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/jir.1992.12.199","volume":"12","author":"K Hellstrand","year":"1992","unstructured":"Hellstrand K, Kylefjord H, Asea A, Hermodsson S (1992) Regulation of the NK-cell response to IFN-? by biogenic amines. J Interferon Res 12: 199?206","journal-title":"J Interferon Res"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02170890","volume":"1","author":"E Hersh","year":"1989","unstructured":"Hersh E, Lee Murray J, Ki Hong W, et al (1989) Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection. Biotherapy 1: 215?226","journal-title":"Biotherapy"},{"key":"CR11","first-page":"4","volume":"4","author":"RK Oldham","year":"1992","unstructured":"Oldham RK, Blumenschein G, Schwartzberg L, et al (1992) Combination biotherapy utilizing interleukin-2 and ? interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother 4: 4?9","journal-title":"Mol Biother"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.1990.8.10.1650","volume":"8","author":"DR Parkinson","year":"1990","unstructured":"Parkinson DR, Abrams JS, Wiernik PH, et al (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8: 1650?1656","journal-title":"J Clin Oncol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00001622-199104000-00020","volume":"3","author":"N Thatcher","year":"1991","unstructured":"Thatcher N (1991) Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma. Curr Opin Oncol 3: 364?376","journal-title":"Curr Opin Oncol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0065-2776(08)60664-1","volume":"47","author":"G Trinchieri","year":"1989","unstructured":"Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47: 187?376","journal-title":"Adv Immunol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/jnci\/83.17.1250","volume":"83","author":"RP Whitehead","year":"1991","unstructured":"Whitehead RP, Kopecky K, Samson MK, et al (1991) Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst 83: 1250?1253","journal-title":"J Natl Cancer Inst"},{"key":"CR16","first-page":"177","volume":"13","author":"RP Whitehead","year":"1992","unstructured":"Whitehead RP, Figlin R, Citron ML, et al (1992) A phase II trial of concomitant human interleukin-2 and interferon ?-2a in patients with disseminated malignant melanoma. J Immunother 13: 177?221","journal-title":"J Immunother"}],"container-title":["Cancer Immunology Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01534430\/fulltext.html","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01534430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01534430\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01534430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:28:01Z","timestamp":1683073681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01534430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,11]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1994,11]]}},"alternative-id":["BF01534430"],"URL":"https:\/\/doi.org\/10.1007\/bf01534430","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,11]]}}}